Carfilzomib

Carfilzomib is a specialized medication used for treating multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. It belongs to a class of drugs called proteasome inhibitors, which work by inhibiting the action of proteasomes, cellular structures responsible for breaking down and disposing of unneeded or damaged proteins.
By disrupting the proteasome function, Carfilzomib allows the accumulation of damaged proteins in the cancerous plasma cells, ultimately leading to their death. This helps slow down the progression of the disease and alleviate symptoms.
Carfilzomib is typically administered in combination with other cancer-fighting agents, such as dexamethasone and lenalidomide, to enhance its therapeutic efficacy. This approach has been shown to improve the overall survival rate and quality of life for patients with multiple myeloma, especially those with relapsed or refractory disease.
It is essential for healthcare professionals to closely monitor patients receiving Carfilzomib for potential side effects, such as decreased blood pressure, inflammation of the heart, or impairment of kidney function. These side effects may require adjustments to the treatment plan or additional interventions to ensure patient safety and well-being.